SCHEMBL1379725

SCHEMBL1379725

CCN(Cc1nc(-c2cccc(C(=O)NC)c2)oc1C)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1

nearest known ligand 0.73

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 13/20 0.73
NR1H3 Q13133 13/20 0.73
LMNA P02545 2/20 0.40
ALDH1A1 P00352 1/20 0.40
TP53 P04637 2/20 0.38
MAPT P10636 2/20 0.38
POLB P06746 1/20 0.38
KDM4E B2RXH2 1/20 0.37
USP2 O75604 1/20 0.37
GAA P10253 1/20 0.37
ALOX15 P16050 1/20 0.37
TSHR P16473 1/20 0.37
MAPK1 P28482 1/20 0.37
HTT P42858 1/20 0.37
GFER P55789 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
HSD17B10 Q99714 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
DHFR P00374 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1382860 0.91 NR1H2 (0.77) NR1H2NR1H3LMNAALDH1A1DHFR
SCHEMBL1383716 0.90 NR1H2 (0.66) NR1H2NR1H3TP53MAPTPOLB
SCHEMBL2080791 0.90 NR1H2 (0.73) NR1H2NR1H3LMNAALDH1A1TP53
SCHEMBL1382717 0.90 NR1H2 (0.76) NR1H2NR1H3LMNAALDH1A1DHFR
SCHEMBL1386493 0.89 NR1H2 (0.75) NR1H2NR1H3LMNAALDH1A1DHFR
SCHEMBL1380958 0.85 NR1H2 (1.00) NR1H2NR1H3LMNAALDH1A1MAPT
SCHEMBL1381813 0.84 NR1H2 (1.00) NR1H2NR1H3LMNATP53MAPT
SCHEMBL1379781 0.81 NR1H2 (0.68) NR1H2NR1H3TP53MAPT
SCHEMBL5566741 0.81 NR1H2 (0.60) NR1H2NR1H3MAPT
SCHEMBL1379075 0.81 NR1H2 (0.65) NR1H2NR1H3TP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4809338-B2 2011-11-09 JP claimed
US-7259178-B2 Containing an oxazole ring, e.g., 1,1,1,3,3,3-Hexafluoro-2-{4-[[5-methyl-2-(3-trifluoromethyl-phenyl)-oxazol-4-ylmethyl]-(2,2,2-trifluoro-ethyl)-amino]-phenyl}-propan-2-ol; the compounds bind to and selectively activate LXR alpha and LXR beta; used to treat diseases such as atherosclerosis and diabetes HOFFMANN-LA ROCHE INC. (US) 2007-08-21 US claimed
EP-1763502-A1 NOVEL HEXAFLUOROISOPROPANOL DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2007-03-21 EP claimed
US-20060004068-A1 Novel hexafluoroisopropanol derivatives F. HOFFMANN-LA ROCHE AG (CH) 2006-01-05 US claimed
WO-2006000323-A1 NOVEL HEXAFLUOROISOPROPANOL DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2006-01-05 WO claimed
US-7897815-B2 Hexafluoroisopropanol derivatives HOFFMANN-LA ROCHE INC. (US) 2011-03-01 US disclosed
US-20100004297-A1 NOVEL HEXAFLUOROISOPROPANOL DERIVATIVES DEHMLOW HENRIETTA 2010-01-07 US disclosed
US-7608721-B2 Hexafluoroisopropanol derivatives HOFFMANN-LA ROCHE INC. (US) 2009-10-27 US disclosed
US-20080096937-A1 Novel hexafluoroisopropanol derivatives DEHMLOW HENRIETTA 2008-04-24 US disclosed
US-20070213377-A1 Novel hexafluoroisopropanol derivatives DEHMLOW HENRIETTA 2007-09-13 US disclosed
US-7259178-B2 Containing an oxazole ring, e.g., 1,1,1,3,3,3-Hexafluoro-2-{4-[[5-methyl-2-(3-trifluoromethyl-phenyl)-oxazol-4-ylmethyl]-(2,2,2-trifluoro-ethyl)-amino]-phenyl}-propan-2-ol; the compounds bind to and selectively activate LXR alpha and LXR beta; used to treat diseases such as atherosclerosis and diabetes HOFFMANN-LA ROCHE INC. (US) 2007-08-21 US disclosed
EP-1763502-A1 NOVEL HEXAFLUOROISOPROPANOL DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2007-03-21 EP disclosed
US-20060004068-A1 Novel hexafluoroisopropanol derivatives F. HOFFMANN-LA ROCHE AG (CH) 2006-01-05 US disclosed
WO-2006000323-A1 NOVEL HEXAFLUOROISOPROPANOL DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2006-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213377-A1 Novel hexafluoroisopropanol derivatives NR1H3, NR1H2, NR1I2 NR1H2 2/4885NR1H3 1/4885LMNA 2780/4885
US-20100004297-A1 NOVEL HEXAFLUOROISOPROPANOL DERIVATIVES NR1H3, NR1H2, NR1I2 NR1H2 2/4885NR1H3 1/4885LMNA 2780/4885
US-20080096937-A1 Novel hexafluoroisopropanol derivatives NR1H3, NR1H2, NR1I2 NR1H2 2/4885NR1H3 1/4885LMNA 2780/4885
US-20060004068-A1 Novel hexafluoroisopropanol derivatives NR1H3, NR1H2, NR1I2 NR1H2 2/4885NR1H3 1/4885LMNA 2780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.